Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
2004/08/17 by Maria L. Macheda, Suzanne Rogers, James D. Best · 29 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Metabolism, Diabetes, and Cancer #Cancer, Hypoxia, and Metabolism #Bone health and treatments
paper · pdf · doi:10.1002/jcp.20166
Abstract
Malignant cells are known to have accelerated metabolism, high glucose requirements, and increased glucose uptake. Transport of glucose across the plasma membrane of mammalian cells is the first rate-limiting step for glucose metabolism and is mediated by facilitative glucose transporter (GLUT) proteins. Increased glucose transport in malignant cells has been associated with increased and deregulated expression of glucose transporter proteins, with overexpression of GLUT1 and/or GLUT3 a characteristic feature. Oncogenic transformation of cultured mammalian cells causes a rapid increase of glucose transport and GLUT1 expression via interaction with GLUT1 promoter enhancer elements. In human studies, high levels of GLUT1 expression in tumors have been associated with poor survival. Studies indicate that glucose transport in breast cancer is not fully explained by GLUT1 or GLUT3 expression, suggesting involvement of another glucose transporter. Recently, a novel glucose transporter protein, GLUT12, has been found in breast and prostate cancers. In human breast and prostate tumors and cultured cells, GLUT12 is located intracellularly and at the cell surface. Trafficking of GLUT12 to the plasma membrane could therefore contribute to glucose uptake. Several factors have been implicated in the regulation of glucose transporter expression in breast cancer. Hypoxia can increase GLUT1 levels and glucose uptake. Estradiol and epidermal growth factor, both of which can play a role in breast cancer cell growth, increase glucose consumption. Estradiol and epidermal growth factor also increase GLUT12 protein levels in cultured breast cancer cells. Targeting GLUT12 could provide novel methods for detection and treatment of breast and prostate cancer.
Cited by
- New strategies for targeting glucose metabolism–mediated acidosis for colorectal cancer therapy
- Azide based routes to tetrazolo and oxadiazolo derivatives of pyrrolobenzodiazepines and pyrrolobenzothiadiazepines
- Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review
- Turn-on fluorescent glucose transport bioprobe enables wash-free real-time monitoring of glucose uptake activity in live cells and small organisms
- Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. [europepmc]
- GLUT1 and GLUT9 as major contributors to glucose influx in HepG2 cells identified by a high sensitivity intramolecular FRET glucose sensor. [europepmc]
- Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. [europepmc]
- Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. [europepmc]
- 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. [europepmc]
- Acidic stress promotes a glioma stem cell phenotype. [europepmc]
- Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. [europepmc]
- GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. [europepmc]
- Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. [europepmc]
- Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. [europepmc]
- Glucose transporters in cancer metabolism. [europepmc]
- Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. [europepmc]
- Molecular imaging for cancer diagnosis and surgery. [europepmc]
- Tumor glycolysis as a target for cancer therapy: progress and prospects. [europepmc]
- Metabolic signature identifies novel targets for drug resistance in multiple myeloma. [europepmc]
- Calcium homeostasis and ER stress in control of autophagy in cancer cells. [europepmc]
- The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate. [europepmc]
- Multicomponent peptide assemblies. [europepmc]
- The Influence of Metabolism on Drug Response in Cancer. [europepmc]
- Obesity, DNA Damage, and Development of Obesity-Related Diseases. [europepmc]
- Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment. [europepmc]
- Metabolic Reprogramming in Triple-Negative Breast Cancer. [europepmc]
- The usefulness of lactate dehydrogenase measurements in current oncological practice. [europepmc]
- A guide to plasma membrane solute carrier proteins. [europepmc]
- Tumor biomarkers for diagnosis, prognosis and targeted therapy. [europepmc]
Related